Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

90 results about "Valproic Acid" patented technology

This medication is used to treat seizure disorders, mental/mood conditions (such as manic phase of bipolar disorder), and to prevent migraine headaches.

Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg / day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
Owner:JAZZ PHARMACEUTICALS OPERATIONS UK LTD

Method for controlling process impurity 2-ethyl valeric acid in valproic acid

The invention belongs to the technical field of separation of drug intermediates, and particularly relates to a control method for a process impurity 2-ethyl valeric acid (EP-B) in preparation of valproic acid or sodium valproate by a diethyl malonate method. According to the method disclosed by the invention, the content of 2-ethyl-2-propylmalonic acid process impurities in dipropylmalonic acid is controlled, so that the content of 2-ethylvaleric acid (EP-B) which is a process impurity in valproic acid or sodium valproate is accurately controlled; adding a polar solvent into the dipropylmalonic acid crude product, heating, pulping for a certain time, cooling, filtering and drying to obtain a high-purity dipropylmalonic acid refined product; high-purity valproic acid (RRT is equal to 1.00) is prepared through decarboxylation of the dipropyl malonic acid fine product, and the purity is 99.779%; 0.020% of 2-ethyl valeric acid (RRT is equal to 0.90); and valeric acid (RRT = 0.77), 0.039%. The valproic acid product quality meets the requirements of European Pharmacopoeia. According to the method, the problems of quality control and process evaluation of valproic acid or sodium valproate prepared by a diethyl malonate method are solved.
Owner:HUNAN UNIV

Post-treatment method for preparing dipropylmalonic acid crude product by dimethyl malonate method

The invention belongs to the technical field of separation of drug intermediates, and particularly relates to a method for preparing a high-purity dipropylmalonic acid refined product by adding a polar solvent into a dipropylmalonic acid crude product, heating, pulping for a certain time, cooling, filtering and drying. Decarboxylating the refined dipropylmalonic acid product to obtain high-purity valproic acid; distilling the filtrate to recover the polar solvent to obtain 2-methyl-2-propylmalonic acid, and carrying out decarboxylation on the 2-methyl-2-propylmalonic acid to obtain 2-methylpentanoic acid; 2-methylvaleric acid is used as a perfume additive. According to the method disclosed by the invention, the process impurity 2-methyl-2-propylmalonic acid in dipropylmalonic acid is separated, and the process impurity 2-methylvaleric acid (EP-L) in valproic acid or sodium valproate is precisely separated; the quality of the valproic acid product prepared by the method disclosed by the invention meets the requirements of European Pharmacopoeia EP-11 (2023). According to the invention, the problems of quality control and process evaluation of valproic acid or sodium valproate prepared by a dimethyl malonate method are solved.
Owner:HUNAN UNIV

Application of Trolox in preparation of medicine for treating toxicity caused by valproic acid

The invention discloses application of Trolox in preparation of a medicine for treating toxicity caused by valproic acid, and belongs to the technical field of biological medicine. The invention discovers for the first time that Trolox has a new medicine application of preventing and / or treating developmental toxicity caused by valproic acid or redox level imbalance caused by valproic acid; furthermore, animal experiments prove that Trolox can relieve zebra fish development malformation caused by valproic acid and also can relieve zebra fish redox level imbalance caused by valproic acid; this provides a new solution for the prevention and / or treatment of developmental toxicity caused by valproic acid or redox level imbalance caused by valproic acid.
Owner:HUBEI UNIV OF TECH

Preparation method and application of mesenchymal stem cell source exosome entrapped valproic acid compound

The invention belongs to the field of biological medicine, and discloses a preparation method and application of a mesenchymal stem cell-derived exosome entrapped valproic acid compound. According to the invention, the mesenchymal stem cell source exosome is used as a carrier, valproic acid is entrapped, and the compound of VPA entrapped by the exosome of MSCs is prepared by an ultrasonic method, so that the VPA-EXO prepared by the invention is proved to be capable of promoting faster repair of the wound surface by inhibiting inflammation, promoting collagen formation, accelerating angiogenesis and reepithelization of the wound surface. The valproic acid-loaded human umbilical cord mesenchymal stem cell exosome prepared by the invention is VPA-EXO prepared by an ultrasonic method, has no obvious toxicity to cells, and has obvious advantages.
Owner:SHANGHAI YANHUA ZHONGKANG BIOMEDICAL CO LTD

Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health

A method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy-inducing compounds. In one embodiment, the one or more autophagy-inducing compounds are selected from the group consisting of thymol, carvacrol, spermidine, urolithin (e.g., Urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5′ AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g. beta-hydroxybutyrate, ketone salts, or ketone ester derivatives), 4,4′-dimethoxychalcone and mixtures thereof.
Owner:SOCIETE DES PRODUITS NESTLE SA

Sodium valproate sustained release tablet with stable crystal form and preparation method of sodium valproate sustained release tablet

The invention provides a sodium valproate sustained release tablet with a stable crystal form and a preparation method of the sodium valproate sustained release tablet, and relates to the technical field of pharmacy. The preparation method comprises the following steps: dissolving sodium valproate, valproic acid and ethyl cellulose in a solvent to prepare a medicine solution; putting hydroxypropyl methylcellulose and silicon dioxide into a fluidized bed, controlling the air inlet volume, the air inlet temperature and the atomization pressure, spraying the medicine solution into a fluidization chamber, maintaining the material temperature to be stable, granulating, finishing granules, adding saccharin sodium salt and colloidal silicon dioxide, and totally mixing; tabletting to obtain a tablet core; and controlling the temperature of the tablet bed, and coating the tablet core to prepare the sodium valproate sustained-release tablet. The preparation process is simple, the sodium valproate and the valproic acid can be fully contacted to form a complete solvate, the obtained preparation is consistent in crystal form between batches, the crystal form is stable in the storage process, and the medicine can be continuously and stably released within 24 hours.
Owner:JINZHOU AHON PHARM CO LTD

Lithium valproate and crystal form, preparation method, pharmaceutical composition and application thereof

The invention relates to the technical field of medicinal chemistry, in particular to lithium valproate and a crystal form, a preparation method, a pharmaceutical composition and application thereof. The crystal forms of the lithium valproate comprise a crystal form I, a crystal form II, a crystal form III, a crystal form IV, a crystal form V, a crystal form VI and a crystal form VII. The lithium valproate provided by the invention has a more comprehensive treatment effect on nervous system diseases, and is good in curative effect and good in stability.
Owner:SHENZHEN FONCOO PHARMACEUTICAL CO LTD

Application of injectable bioactive hydrogel in treatment of recurrent abortion

PendingCN120661437APeptide/protein ingredientsAerosol deliveryRecurrent miscarriageValproic Acid
The invention provides application of injectable bioactive hydrogel in treatment of recurrent abortion, and relates to the technical field of biomedicine, and the technical key points are as follows: aldehydic hyaluronic acid and chitosan are connected in parallel, the injectable bioactive hydrogel is developed, and the hydrogel is loaded with LIF, VEGF, IL-11 and valproic acid to enhance regeneration activity. According to the application, the effect is evaluated in vitro through a specific verification experiment. Results show that the hydrogel prepared by the application shows rapid gelation, good biocompatibility and factor loading capacity, and enhances the proliferation of human endometrial stromal cells and the vascularization capacity of human umbilical vein endothelial cells. In macrophages, the expression of a proinflammatory cytokine is down-regulated, and the expression of an anti-inflammatory cytokine IL-10 is up-regulated. In conclusion, the HA-CHO / chitosan hydrogel in the application supports endometrial regeneration by synergistically promoting proliferation, angiogenesis, immune regulation and receptivity.
Owner:AFFILIATED HOSPITAL OF NANTONG UNIV

Methods and compositions for treating cancers

To provide a novel therapeutic strategy for treating cancers expressing embryonic antigens.SOLUTION: The inventors have developed a metastatic 4T1 breast tumor model in BALB / c mice. The inventors have showed that vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher antitumor response against a breast cancer and inhibits metastasis development. The inventors have demonstrated that these responses are only achieved by the addition of valproic acid in a therapeutic regimen compared to the use of ESC or iPSC alone. Thus, the inventors provide a novel therapeutic strategy for treating cancers expressing embryonic antigens. The present invention therefore relates to a method for treating a subject suffering from cancer, comprising the steps of administering to the subject simultaneously, separately or sequentially a therapeutic amount of i) a population of pluripotent cells and ii) a compound selected from the group that activates MHC expression as a combined preparation.SELECTED DRAWING: None
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Compositions and methods for pretreatment of cancer

The present invention relates to a pharmaceutical composition for oral administration, the pharmaceutical composition comprising: a) immediate-release granules comprising i. an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and ii. a filler; and b) sustained-release pellets comprising: i. a pellet core comprising (1) an active ingredient selected from the group consisting of valproic acid, semi-sodium valproic acid, sodium valproic acid, and magnesium valproic acid, and (2) a filler; and ii. on the pellet core iii. A sustained-release pellet comprising a subcoat provided on the subcoat, the content of which is 10 to 20% by weight based on the weight of the pellet core and contains a film-forming agent, and iii. a sustained-release coating provided on the subcoat, the content of which is 25 to 100% by weight based on the weight of the pellet core coated with the subcoat and contains a film-forming agent, wherein the amount of active ingredient in the immediate-release granules accounts for 70 to 80% by weight of the total weight of active ingredients in the pharmaceutical composition, and the amount of active ingredient in the sustained-release pellets accounts for 20 to 30% by weight of the total weight of active ingredients in the pharmaceutical composition. In yet another aspect, the present invention relates to a method for producing a pharmaceutical composition and a pharmaceutical composition for use in a method of pretreatment of cancer.
Owner:VALCURIA

Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension

The present invention relates to methods of treating / preventing abnormal conditions associated with pulmonary arterial hypertension (PAH) and methods of treating PAH in subjects refractory to treatment for PAH, said methods involving administering to the subject of an effective amount of a of Formula (I), wherein R1 is either H or D and wherein D is deuterium, or a pharmaceutically acceptable salt thereof.
Owner:CERENO SCIENTIFIC AB

Recovery and application of 2-cyano-2-methylvaleric acid

The invention belongs to the field of pharmaceutical chemical engineering and fine chemical engineering, and relates to a method for recovering 2-cyano-2-methylvaleric acid as shown in a chemical structural formula I. The method comprises the following steps: selecting methyl 2-cyanoacetate and 1-chloropropane, and carrying out catalytic dipropylation under the action of potassium carbonate to prepare methyl 2-cyano-2-valproate; hydrolyzing the latter to obtain 2-cyano-2-valproic acid (crude product) as shown in a formula III; adding water, alcohol and other polar solvents into the 2-cyano-2-valproic acid crude product, pulping, carrying out gradient crystallization, filtering, and carrying out low-temperature vacuum drying to obtain 2-cyano-2-valproic acid monohydrate and 2-cyano-2-methylvalproic acid monohydrate; the 2-cyano-2-valproic acid monohydrate is subjected to high-temperature decarboxylation hydrolysis through sulfuric acid, and valproic acid is prepared; and carrying out high-temperature decarboxylation hydrolysis on the 2-cyano-2-methylpentanoic acid monohydrate by using sulfuric acid to obtain the essence 2-methylpentanoic acid.
Owner:HUNAN XIANGZHONG PHARM CO LTD +1

Methods for treating a coronavirus infection using valproic acid and docosahexaenoic acid

Disclosed herein, are methods for treating, preventing or inhibiting a coronavirus infection or a disease or condition associated with a coronavirus infection. The methods can comprise administering to the subject one or more therapeutically effective doses of valproic acid and docosahexaenoic acid.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Application of betaine in the preparation of drugs for treating autism

PendingCN122272617ABetainePhysiology
This invention relates to the field of biomedical technology, specifically disclosing the application of betaine in the preparation of drugs for treating autism. Through experiments using a valproic acid-induced mouse model of autism spectrum disorder, this invention found that betaine can significantly improve social impairments and repetitive, stereotyped behaviors in the model mice, and exhibits stable and reproducible effects in both 1-month-old and 2-month-old male offspring. This invention reveals a novel use of betaine in treating core behavioral deficits in autism spectrum disorder (ASD), providing a new source of natural active ingredients for the preparation of drugs for treating autism.
Owner:SOUTHEAST UNIV

Method for detecting valproic acid key intermediate and impurities thereof

The invention belongs to the technical field of medicine detection, and particularly relates to a high performance liquid chromatography detection method for dipropylmalonic acid and impurities thereof. The method comprises the following steps: preparing a to-be-detected sample into a test solution; the to-be-detected sample is dipropyl malonic acid prepared by adopting a diethyl malonate method and impurities of the dipropyl malonic acid; and detecting the test solution by adopting a high performance liquid chromatography method to obtain a detection result of dipropylmalonic acid and impurities thereof in the sample to be detected. According to the detection method provided by the invention, the detection of dipropylmalonic acid prepared by adopting a diethyl malonate method and impurities thereof is realized through high performance liquid chromatography (HPLC) for the first time, and the problems of quality control and process evaluation of the dipropylmalonic acid prepared by adopting the diethyl malonate method, which is an intermediate of a sodium valproate raw material medicine, are solved; therefore, detection and control of impurities (including 2-ethyl valeric acid) in the sodium valproate raw material medicine are realized.
Owner:HUNAN XIANGZHONG PHARM CO LTD

Method of treating social deficits with class i HDAC inhibitors

The present technology generally relates to methods of treating social deficits with HDAC inhibitors. Select embodiments of the present technology include a method for treating organophosphate induced social deficits in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an HDAC inhibitor selected from the group consisting of valproic acid, butyric acid, BRD-6929, RGFP966, pharmaceutically acceptable salts thereof, and combinations thereof. The subject may have been diagnosed with a disease or disorder characterized by social deficits, such as autism spectrum disorder. The subject may be monitored for a change in the severity of social deficits.
Owner:UNIV OF WASHINGTON

S-adenosyl methionine (SAME) and valproic acid (VPA) combinations for preventing VPA-induced congenital malformations

The present invention relates to a combination of valproic acid (VPA) and S- adenosylmethionine (SAMe) for use in preventing congenital malformations in a fetus of a subject in need of VPA treatment and who is pregnant or intends to become pregnant, by administering the combination to the subject before or during the first trimester of pregnancy, wherein the SAMe and the VPA are at a ratio of about 1:10-1:50 w / w SAMe:VPA in the combination; and corresponding methods of treatment.
Owner:ARIEL SCI INNOVATIONS LTD

Lithium valproate and crystal forms thereof, preparation method therefor, pharmaceutical composition thereof and use thereof

PCT designated stageWO2026138683A1Valproic AcidPharmaceutical drug
The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to lithium valproate and crystal forms thereof, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. The crystal forms of lithium valproate comprise crystal form I, crystal form II, crystal form III, crystal form IV, crystal form V, crystal form VI and crystal form VII.
Owner:SHENZHEN FONCOO PHARMACEUTICAL CO LTD

Application of valproic acid in preparation of medicine for preventing and / or treating lung fibroblast and lung tissue aging

The invention belongs to the technical field of biological medicine, and particularly relates to application of valproic acid in preparation of medicine for preventing and / or treating lung fibroblast and lung tissue senescence, the medicine induces the senescent lung fibroblast to excessively accumulate active oxygen in the cell, so that excessive autophagy of the cell is induced, senescent cell apoptosis is caused, and the effect of preventing and / or treating lung fibroblast and lung tissue senescence is achieved. And finally, the lung aging is relieved. The invention provides a new medicine source for preventing, intervening, delaying and researching aging of lung fibroblasts and lung tissues. The medicine for promoting apoptosis of aging cells in vitro or in the lung tissues, provided by the invention, is safe, relatively strong in pharmacological action, small in side effect and definite in curative effect.
Owner:YANGZHOU FIRST PEOPLES HOSPITAL

Methods for improving cognitive function

A method for improving cognitive function of a subject which includes administering a composition containing dextromethorphan or valproic acid to the subject in need thereof. The composition containing the dextromethorphan is used for improving the sustained attention of the subject. The composition containing the valproic acid is used for improving the memory of the subject.
Owner:LU RU BAND

A HPLC-MSMS method for simultaneous determination of valproic acid, olanzapine and its metabolites in plasma

The application discloses a kind of HPLC-MSMS method for simultaneously determining valproic acid, olanzapine and its metabolites in plasma, which comprises the following steps: S1. pretreatment of plasma samples with acetonitrile protein precipitation method;S2. HPLC-MSMS method is used to detect plasma samples, and qualitative and / or quantitative analysis of valproic acid, olanzapine and its metabolites in plasma is carried out simultaneously;Wherein, Agilent Poroshell 120EC-C18 column is selected as the chromatographic column;Electrospray ion source is used, and the mobile phase is A phase: formic acid water, B phase: acetonitrile;By optimizing the conditions of liquid phase and mass spectrometry, valproic acid, olanzapine and its metabolites are simultaneously determined by one method.The method has been applied to detect plasma samples of olanzapine and valproic acid combination, and olanzapine alone, and the measured results all meet the linear range.
Owner:JIANGXI ZHONGKE YANYANG BIOTECHNOLOGY CO LTD

Application of 3-oxo-valproate coenzyme A in preparation of medicine for inhibiting lung adenocarcinoma

The invention belongs to the technical field of biological medicine and tumor immunotherapy, and discloses application of 3-oxo-valproic acid coenzyme A in preparation of a medicine for inhibiting lung adenocarcinoma. As a specific agonist of GIMAP1, the 3-oxo-valproic acid coenzyme A is used for activating the GIMAP1, enhancing inhibition of lung cancer cell progress and enhancing activation of a tumor immune microenvironment, so that the lung adenocarcinoma is inhibited, and the lung adenocarcinoma is inhibited. The invention has the following beneficial effects: 1, strong targeting property: 3-oxo-valproate coenzyme A is specifically combined with GIMAP1, so that a mediated immunomodulatory pathway is accurately activated, and wide influence on normal cells is avoided; 2, immune microenvironment remodeling: the anti-tumor immune cell infiltration is remarkably improved, the lung adenocarcinoma immunosuppression microenvironment is reversed, and the immunotherapy sensitivity is improved; 3, tumor progression is inhibited, lung cancer cell proliferation is effectively inhibited, and the tumor invasion ability is reduced; 4, the source is natural: as an intestinal microbial metabolite derivative, the safety is high, and the side effect is lower than that of a chemically synthesized medicine.
Owner:YONGZHOU VOCATIONAL & TECH COLLEGE

A compound and its application

This invention belongs to the field of medicinal chemistry and discloses a compound and its use. The compound, represented by Formula I, or its stereoisomers, provided herein can effectively alleviate behavioral disturbances exhibited in a rat model of autism induced by valproic acid, providing a potential candidate for the development of novel autism treatments.
Owner:CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD

Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and / or thrombus formation

ActiveUS12245999B2Valproic AcidThrombus
There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and / or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.
Owner:CERENO SCIENTIFIC AB

Valproic acid homogeneous enzyme immunoassay kit, preparation method and application

The invention relates to a valproic acid homogeneous enzyme immunoassay kit and a preparation method and application thereof, the valproic acid homogeneous enzyme immunoassay kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises a buffer solution, a mouse anti-valproic acid monoclonal antibody, L-malic acid, a stabilizer, a preservative and a surfactant; and the R2 reagent comprises a buffer solution, beta-NAD < + >, a malate dehydrogenase-valproic acid conjugate, a protective agent and a preservative. Aiming at the defect that an existing valproic acid homogeneous enzyme immunoassay kit is poor in stability, glucose 6-phosphate dehydrogenase in a system is replaced with malic dehydrogenase, so that the analysis sensitivity, precision, thermal stability and long-term stability of the kit are remarkably improved. Various performance indexes of the kit are further improved by adjusting the content of the malate dehydrogenase-valproic acid conjugate and beta-NAD < + > in the system, so that the valproic acid homogeneous enzyme immunoassay kit with high analysis sensitivity and excellent precision and stability is obtained.
Owner:ZHONGSHAN CHUANGYI BIOCHEM ENG

Pluripotent stem cells transformed from human placental fibroblasts and induction method thereof

The invention relates to the technical field of somatic cell reprogramming and cell transplantation therapy, in particular to a chemical induction method for reprogramming human placenta fibroblasts into pluripotent stem cells, which comprises the following steps: taking in-vitro human placenta fibroblasts, and reprogramming the in-vitro human placenta fibroblasts into induced epithelial-like cells under the action of TTNPB, calorphin, RepSox, Tranylcyromine and valproic acid; according to the method, the induced epithelial cells are subjected to continuous induction by utilizing a piripotent element, RepSox, TTNPB, Tranylcyromine, valproic acid, EPZ004777, AM580, CHIR99021 and DZNep, and finally, the induced pluripotent stem cells are obtained. According to the method, the reprogramming process only comprises two specific stages, the induction duration is greatly shortened, and the reprogramming cell induction efficiency is 0.0678% + / -0.0055%-0.0719% + / -0.0185%.
Owner:BENGBU MEDICAL COLLEGE

Recovery method of 2-cyano-2-valproic acid

The invention relates to a recovery method of 2-cyano-2-valproic acid as shown in a chemical structural formula I. The recovery method is characterized in that 2-cyano-2-valproic acid as shown in a formula II is prepared by catalytic dipropylation of cyanoacetate and 1-chloropropane under the action of K2CO3: # imgabs0 # R is selected from methyl, ethyl, propyl, isopropyl, butyl, tertiary butyl or amyl; pTC is selected from quaternary ammonium salts; in a process for preparing 2-cyano-2-valproate as shown in a formula II, 2-cyano-2-potassium valproate K remaining in inorganic salt is dissolved in water and acidified into 2-cyano-2-valproic acid as shown in a formula I; and extracting with an organic solvent, and distilling to obtain the 2-cyano-2-valproic acid. # imgabs1 #
Owner:HUNAN XIANGZHONG PHARM CO LTD +1

Modified release valproic acid softgel capsule

Softgel capsules comprise a fill composition and a shell composition, wherein the fill composition includes valproic acid and the shell composition includes gelatin, a plasticizer, and an enteric polymer. The softgel capsules further include from 125 mg to 1000 mg dosing of valproic acid. A method for producing the softgel capsule using a gel mass and rotary die encapsulation is also provided.
Owner:R P SCHERER TECH INC

Valproic acid for use in treating pulmonary arterial hypertension

The present invention relates to valproic acid for use in treating and / or preventing pulmonary arterial hypertension (PAH), wherein the treatment and / or prevention comprises administering to a subject a total daily dose of from about 200 mg to about 600 mg of valproic acid or a pharmaceutically acceptable salt thereof.
Owner:CERENO SCIENTIFIC AB